Michael V. Henley

1.1k total citations
38 papers, 597 citations indexed

About

Michael V. Henley is a scholar working on Atmospheric Science, Pulmonary and Respiratory Medicine and Health, Toxicology and Mutagenesis. According to data from OpenAlex, Michael V. Henley has authored 38 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Atmospheric Science, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Health, Toxicology and Mutagenesis. Recurrent topics in Michael V. Henley's work include Atmospheric chemistry and aerosols (8 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers) and Air Quality and Health Impacts (4 papers). Michael V. Henley is often cited by papers focused on Atmospheric chemistry and aerosols (8 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers) and Air Quality and Health Impacts (4 papers). Michael V. Henley collaborates with scholars based in United States, United Kingdom and Germany. Michael V. Henley's co-authors include Carrie A. Delcomyn, Benjamin Krämer, J. Hearn, Carlos Disdier, Leonard Dunn, Cheryl Lassen, Roland Buhl, Howard T. Mayfield, James R. Long and C. Verkindre and has published in prestigious journals such as Environmental Science & Technology, Analytical Chemistry and The Science of The Total Environment.

In The Last Decade

Michael V. Henley

37 papers receiving 575 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael V. Henley United States 14 187 167 90 65 63 38 597
Xiangliang Liu China 14 48 0.3× 201 1.2× 23 0.3× 61 0.9× 56 0.9× 84 728
Juan Cheng China 19 124 0.7× 88 0.5× 367 4.1× 23 0.4× 44 0.7× 78 883
Mariella Carrieri Italy 21 106 0.6× 55 0.3× 590 6.6× 80 1.2× 32 0.5× 72 1.3k
Helle Holst Denmark 17 64 0.3× 73 0.4× 42 0.5× 66 1.0× 48 0.8× 52 797
Yumeng Shi China 15 42 0.2× 71 0.4× 396 4.4× 21 0.3× 56 0.9× 72 1.0k
Charles F. Reinhardt United States 12 301 1.6× 38 0.2× 371 4.1× 65 1.0× 38 0.6× 21 989
Henry J. Trochimowicz United States 13 256 1.4× 29 0.2× 383 4.3× 68 1.0× 35 0.6× 30 843
Valeria Y. Hebert United States 14 72 0.4× 54 0.3× 162 1.8× 20 0.3× 58 0.9× 21 660
Qingyang Shi China 15 38 0.2× 248 1.5× 138 1.5× 10 0.2× 102 1.6× 35 812

Countries citing papers authored by Michael V. Henley

Since Specialization
Citations

This map shows the geographic impact of Michael V. Henley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael V. Henley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael V. Henley more than expected).

Fields of papers citing papers by Michael V. Henley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael V. Henley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael V. Henley. The network helps show where Michael V. Henley may publish in the future.

Co-authorship network of co-authors of Michael V. Henley

This figure shows the co-authorship network connecting the top 25 collaborators of Michael V. Henley. A scholar is included among the top collaborators of Michael V. Henley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael V. Henley. Michael V. Henley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Henley, Michael V., et al.. (2024). Decoding clinical trial jargon: helping people understand theefficacy end points used in cancer trials. Future Oncology. 21(1). 11–14.
2.
Brown, Laura C., et al.. (2015). Characterization of Hazardous Ice Using Radarsat-2 and Ice Profiling Sonar. Proceedings of the International Conference on Port and Ocean Engineering Under Arctic Conditions. 1 indexed citations
3.
Henley, Michael V., et al.. (2014). Health assessment of gasoline and fuel oxygenate vapors: Generation and characterization of test materials. Regulatory Toxicology and Pharmacology. 70(2). S13–S17. 25 indexed citations
4.
Hearn, J., et al.. (2014). Effect of soil moisture on chlorine deposition. Journal of Hazardous Materials. 267. 81–87. 5 indexed citations
5.
Hearn, J., et al.. (2013). Deposition of Cl2 on soils during outdoor releases. Journal of Hazardous Materials. 252-253. 107–114. 17 indexed citations
6.
Hearn, J., et al.. (2012). Cl2 deposition on soil matrices. Journal of Hazardous Materials. 237-238. 307–314. 11 indexed citations
7.
Korn, S, Jutta Beier, D Jadayel, et al.. (2012). P191 QVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT study: Abstract P191 Table 1. Thorax. 67(Suppl 2). A147.1–A147. 5 indexed citations
8.
Buhl, Roland, Leonard Dunn, Carlos Disdier, et al.. (2011). Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. European Respiratory Journal. 38(4). 797–803. 101 indexed citations
9.
Jang, Myoseon, et al.. (2011). The effects of active chlorine on photooxidation of 2-methyl-2-butene. The Science of The Total Environment. 409(13). 2652–2661. 3 indexed citations
10.
Magnussen, H, C. Verkindre, Damon Jack, et al.. (2010). Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respiratory Medicine. 104(12). 1869–1876. 23 indexed citations
11.
Vogelmeier, Claus, C. Verkindre, D. Cheung, et al.. (2010). Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulmonary Pharmacology & Therapeutics. 23(5). 438–444. 48 indexed citations
12.
Henley, Michael V., et al.. (2006). Reverse osmosis processing of organic model compounds and fermentation broths. Bioresource Technology. 98(3). 686–695. 27 indexed citations
13.
Delcomyn, Carrie A., et al.. (2005). Determination of in situ-generated dimethyldioxirane from an aqueous matrix using selected ion monitoring. Journal of Chromatography A. 1089(1-2). 211–218. 4 indexed citations
14.
Reeve, J., Heikki Kröger, Jo Nijs, et al.. (1996). Radial cortical and trabecular bone densities of men and women standardized with the European forearm phantom. Calcified Tissue International. 58(3). 135–143. 25 indexed citations
15.
Henley, Michael V., et al.. (1995). The Effects of Differing Concentrations of Bupivacaine on the Epidural Somatosensory Evoked Potential After Posterior Tibial Nerve Stimulation. Anesthesia & Analgesia. 81(1). 147–151. 14 indexed citations
16.
Senior, Roxy, B. S. Sridhara, Sumit Basu, et al.. (1994). Comparison of radionuclide ventriculography and 2D echocardiography for the measurement of left ventricular ejection fraction following acute myocardial infarction. European Heart Journal. 15(9). 1235–1239. 38 indexed citations
17.
Henley, Michael V., et al.. (1993). Prognostic value of noninvasive cardiac tests in the assessment of patients with peripheral vascular disease. The American Journal of Cardiology. 71(1). 40–44. 11 indexed citations
18.
Dobbs, R. John, S. G. Bowes, André Charlett, et al.. (1993). Hypothesis: the bradyphrenia of parkinsonism is a nosological entity. Acta Neurologica Scandinavica. 87(4). 255–261. 19 indexed citations
19.
Dobbs, R. John, S. G. Bowes, Michael V. Henley, et al.. (1993). Assessment of the bradyphrenia of parkinsonism: a novel use of delayed auditory feedback. Acta Neurologica Scandinavica. 87(4). 262–267. 8 indexed citations
20.
Bowes, S. G., R. John Dobbs, Michael V. Henley, et al.. (1992). Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa. European Journal of Clinical Pharmacology. 43(5). 483–489. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiangliang Liu Breakdown of academic impact, for papers by Juan Cheng Breakdown of academic impact, for papers by Mariella Carrieri Breakdown of academic impact, for papers by Helle Holst Breakdown of academic impact, for papers by Yumeng Shi Breakdown of academic impact, for papers by Charles F. Reinhardt Breakdown of academic impact, for papers by Henry J. Trochimowicz Breakdown of academic impact, for papers by Valeria Y. Hebert Breakdown of academic impact, for papers by Qingyang Shi
Rankless by CCL
2026